Section 16 of the Canadian Charter of Rights and Freedoms

EXCHANGE OFFER DECLARED UNCONDITIONAL

Retrieved on: 
Monday, April 17, 2023
Communication, Failure, European, Person, SEC Rule 144A, Common stock, Sub, ABN, ABN AMRO, Article, Risk, Initial exchange offering, Offering circular, QIB, Acceptance, Letter, AMRO Bank, Trustee, Section 16.1 of the Canadian Charter of Rights and Freedoms, Transaction, Naamloze vennootschap, CEST, Council, Admission, Section 17 of the Constitution Act, 1867, Triangle, Settlement date, Disclosure, EGM, Section 16 of the Canadian Charter of Rights and Freedoms, Documentation, Euronext Amsterdam, Firmenich, Withdrawal, DCC, DSM, European Parliament, File, Admitted, Importance, Exchange, Shareholder, Settlement, ISIN, Exchange offer, EC, Security (finance), Cryptocurrency, Bank, Liquidation

KAISERAUGST, Switzerland and HEERLEN, Netherlands and GENEVA, April 17, 2023 /PRNewswire/ --

Key Points: 
  • After settlement of the Post-Closing Acceptance Period, the Company intends to implement either the Buy-Out or the Post-Offer Merger and Liquidation
    DSM and Firmenich boards are very pleased to announce that the Company hereby declares the Exchange Offer unconditional.
  • As a result, the Exchange Offer will be settled on 20 April 2023 and the Firmenich Contribution will occur on 8 May 2023.
  • This announcement contains selected, condensed information regarding the Exchange Offer and does not replace the Offering Circular.
  • Accordingly, to be eligible to receive DSM-Firmenich Ordinary Shares under the Exchange Offer, each DSM Shareholder that is a U.S.

EXCHANGE OFFER DECLARED UNCONDITIONAL

Retrieved on: 
Monday, April 17, 2023
Communication, Failure, European, Person, SEC Rule 144A, Common stock, Sub, ABN, ABN AMRO, Article, Risk, Initial exchange offering, Offering circular, QIB, Acceptance, Letter, AMRO Bank, Trustee, Section 16.1 of the Canadian Charter of Rights and Freedoms, Transaction, Naamloze vennootschap, CEST, Council, Admission, Section 17 of the Constitution Act, 1867, Triangle, Settlement date, Disclosure, EGM, Section 16 of the Canadian Charter of Rights and Freedoms, Documentation, Euronext Amsterdam, Firmenich, Withdrawal, DCC, DSM, European Parliament, File, Admitted, Importance, Exchange, Shareholder, Settlement, ISIN, Exchange offer, EC, Security (finance), Cryptocurrency, Bank, Liquidation

DSM and Firmenich boards are very pleased to announce that the Company hereby declares the Exchange Offer unconditional.

Key Points: 
  • DSM and Firmenich boards are very pleased to announce that the Company hereby declares the Exchange Offer unconditional.
  • As a result, the Exchange Offer will be settled on 20 April 2023 and the Firmenich Contribution will occur on 8 May 2023.
  • This announcement contains selected, condensed information regarding the Exchange Offer and does not replace the Offering Circular.
  • Accordingly, to be eligible to receive DSM-Firmenich Ordinary Shares under the Exchange Offer, each DSM Shareholder that is a U.S.

ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Thursday, March 30, 2023
Gastrointestinal disease, Partnership, AACR, Orange County Convention Center, Biotechnology, Research, OXFORD, GPR35, Section 16 of the Canadian Charter of Rights and Freedoms, Discovery, American Association for Cancer Research, Patient, Collection, Cancer, Attention deficit hyperactivity disorder predominantly inattentive, Drug discovery, Biology, Ecosystem, Therapy, Pharmaceutical industry, GI

OXFORD, United Kingdom, March 30, 2023 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today emerged from stealth and announced that it will present the first data from its GPR35 antagonist program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023. The presentation will include a suite of preclinical data highlighting the biological role of GPR35 in GI disease and cancers, outlining the hypothesis that GPR35 activity has the potential to drive pro-oncogenic growth biology in digestive tract cancers, and spotlighting the company's discovery of potent GPR35 inhibitors that demonstrate the ability to prevent GPR35 signaling and tumour growth in a patient-derived cancer model. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • ThirtyFiveBio, which has raised $20 million in seed financing to date, was created in 2021 by M:M Bio Limited (M:M Bio) in partnership with Canaan Partners.
  • Supporting the company's focus on GPR35 inhibition is a collection of pre-clinical data generated by its scientists that highlights the association between GPR35 mutations and GI diseases.
  • This includes research showing that GPR35 variants are linked to irritable bowel disease, and that GPR35 expression is upregulated in GI cancers.
  • Furthermore, study results have demonstrated that commonly dysregulated GI-cancer genes can be reversed by knocking out GPR35 in cancer cells.

Faraday Future Promotes Mr. Yueting Jia to Section 16 Officer Position and Executive Officer, Reporting to the Board of Directors

Retrieved on: 
Wednesday, March 1, 2023
Alternative Vehicles, Fuels, Technology, EV, Electric Vehicles, Vehicle Technology, Automotive, Automotive Manufacturing, Software, Manufacturing, Performance & Special Interest, Hardware, Finance, Ferrari, Internet, Faraday Future, FF, Intelligence, Human resources, Advanced technology, Seychelles Tourism Board, Maybach, Capital market, Ultimate, Administration, Section 16 of the Canadian Charter of Rights and Freedoms, Strategic management, Communication, PT, Oklahoma Secretary of Human Resources and Administration, Bentley, SOP, EPA, Security (finance), Management

Moving forward, both Mr. Jia and Mr. Chen will report to the Board directly.

Key Points: 
  • Moving forward, both Mr. Jia and Mr. Chen will report to the Board directly.
  • The Company’s remaining departments including Finance will continue to report to Mr. Chen with a single reporting line.
  • “The decision to restore founder and Chief Product and User Ecosystem Officer Mr. Jia’s Section 16 officer and executive officer status was a very appropriate decision made after careful consideration by the Board,” said Adam He, Chairman of the Board.
  • Specifically, the Board’s appointment of Mr. Jia to executive officer status signifies FF’s strong commitment to keep the Company’s momentum on track.

Diallo Gordon Named Chief Marketing and Product Officer at Passport Technology

Retrieved on: 
Tuesday, January 10, 2023
Aircraft, Section 16 of the Canadian Charter of Rights and Freedoms, Air force, Information system, University, B2B, Space research, Science and technology in Asia, United States Department of Defense, EVP, Telemetry, Federal Aviation Administration, GM, Government, NASA, USAF, History of the University of Maryland, College Park, Business administration, Research, ARIA, Acquisition, Boeing EC-135, United, Gordon, Weapon, Cryptocurrency, Passport, Phi, Science

LAS VEGAS, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Passport Technology Inc. (Passport) , the fastest-growing provider of payment technology to the global gaming industry, has appointed Diallo Gordon as Chief Marketing and Product Officer.

Key Points: 
  • LAS VEGAS, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Passport Technology Inc. (Passport) , the fastest-growing provider of payment technology to the global gaming industry, has appointed Diallo Gordon as Chief Marketing and Product Officer.
  • "Diallo has proven himself to be a tremendous leader, industry visionary and is an invaluable asset to the Passport team."
  • Passport's solutions are industry-leading and the commitment to service, innovation and collaborative relationships won me over from day one," states Gordon.
  • Gordon holds multiple undergraduate degrees in Electronics Engineering Technology, Business Management and Business Administration.

SEC Adopts Amendments to Modernize Rule 10b5-1 Insider Trading Plans and Related Disclosures

Retrieved on: 
Wednesday, December 14, 2022
Section, Person, Form 4, Security (finance), Disclosure, Form 5, Processor register, Form 10-Q, Congress, 8-K, SEC Rule 10b-5, Section 16 of the Canadian Charter of Rights and Freedoms, Proxy, File, Federal Register, Financial adviser

The amendments include updates to Rule 10b5-1(c)(1), which provides an affirmative defense to insider trading liability under Section 10(b) and Rule 10b-5.

Key Points: 
  • The amendments include updates to Rule 10b5-1(c)(1), which provides an affirmative defense to insider trading liability under Section 10(b) and Rule 10b-5.
  • “About 20 years ago, the SEC established Exchange Act Rule 10b5-1.
  • Specifically, the amendments adopt cooling-off periods for persons other than issuers before trading can commence under a Rule 10b5-1 plan.
  • The amendments will require more comprehensive disclosure about issuers’ policies and procedures related to insider trading, including quarterly disclosure by issuers regarding the use of Rule 10b5-1 plans and certain other trading arrangements by its directors and officers for the trading of its securities.

PLBY Group CEO Ben Kohn and Other Executive Officers to Sell a Portion of Shares from RSU Settlements to Satisfy Tax Obligations

Retrieved on: 
Thursday, December 15, 2022
Cyprus Securities and Exchange Commission, Annual report, RSU, Security (finance), Sale, Freedom, Playboy, Culture, Section 16 of the Canadian Charter of Rights and Freedoms, Pleasure, Exercise, Tax, Risk, COVID-19

Pursuant to the Company's current practices, withholding tax obligations arising from RSU settlements are being satisfied by the sale of shares by the recipients solely to cover the taxes related to such transactions.

Key Points: 
  • Pursuant to the Company's current practices, withholding tax obligations arising from RSU settlements are being satisfied by the sale of shares by the recipients solely to cover the taxes related to such transactions.
  • Following the RSU settlement and his sale to cover tax obligations, Mr. Kohn will beneficially own up to approximately 2.6 million shares, representing approximately 5.4% of the Company’s common stock outstanding.
  • Beneficial ownership is determined according to the rules of the Securities and Exchange Commission, which generally includes options that are currently exercisable or exercisable within 60 days.
  • PLBY Group, Inc. is a global pleasure and leisure company connecting consumers with products, content, and experiences that help them lead more fulfilling lives.

SeaChange Elevates Chris Klimmer to President to Accelerate Streaming & AdTech SaaS Growth Strategy

Retrieved on: 
Wednesday, August 17, 2022
U.S. Securities and Exchange Commission, Section 16 of the Canadian Charter of Rights and Freedoms, Risk, CFA, Industry, Forward-looking statement, GLOBE, Senior, SEAC, Failure, Technology, Growth, SEC, Investment, Leadership, Board, Security (finance), Software as a service, SeaChange International, Comparison of multi-paradigm programming languages, FAST, Broadcast programming, Adtech (company), Free, NASDAQ, Private Securities Litigation Reform Act, Software, Connected, Smart TV, Advertising, SeaChange, Terminology, Television, Video game, Video game console, Management, Company, Nasdaq

SeaChange posted 33% year-over-year revenue growth in our fiscal first quarter 2023, and is methodically moving towards sustainable and profitable growth, said SeaChanges Chairman and Chief Executive Officer, Peter Aquino.

Key Points: 
  • SeaChange posted 33% year-over-year revenue growth in our fiscal first quarter 2023, and is methodically moving towards sustainable and profitable growth, said SeaChanges Chairman and Chief Executive Officer, Peter Aquino.
  • Most importantly, with Chris leading the way, SeaChange is accelerating our focus into higher growth segments of our industry.
  • I am incredibly proud and grateful to get the increased opportunity to lead SeaChange into this new chapter, adds Mr. Klimmer.
  • SeaChange enjoys a rich heritage of nearly three decades of delivering premium video software solutions to its global customer base.

aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Private Securities Litigation Reform Act, Cancer, Risk, IAS, University of Science and Technology, University of Massachusetts Medical School, Investigational New Drug, University, 3D, Transitive relation, ATyr Pharma, Forward-looking statement, Section 16 of the Canadian Charter of Rights and Freedoms, IND, RNA transfection, AACR, SEC, Research, EMT, Metastasis, Antibody, American Association, NRP2, LIFE, Poster, Neoplasm, Neuropilin, Lymphatic system, Association, NPR2, New Orleans Morial Convention Center, VEGF, Biology, Annual general meeting, Goal, CXCR4, COVID-19, Drug resistance, GLOBE, Gene, SAN, Annual report, Breast cancer, Technology, Patient, TNBC, Medical imaging, Pharmaceutical industry

The poster and corresponding abstract are available for browsing on the AACR website through July 13, 2022.

Key Points: 
  • The poster and corresponding abstract are available for browsing on the AACR website through July 13, 2022.
  • Furthermore, ATYR2810 monotherapy inhibited spontaneous lung metastasis in an experimental model of TNBC, demonstrating the potential therapeutic effects of blocking the NRP2/VEGF signaling axis on preventing tumor persistence.
  • These findings suggests that ATYR2810 may serve as a novel therapeutic agent for the treatment of advanced and metastatic cancers.
  • aTyr Pharma, University of Massachusetts Chan Medical School, Pangu BioPharma, IAS HKUST - Scripps R&D, Hong Kong University of Science and Technology.

Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting

Retrieved on: 
Friday, April 1, 2022
Cell, Therapy, Myelodysplastic syndrome, Acute myeloid leukemia, Molecule, Choroid, SMARCA2, AML, SMARCA4, Forward-looking statement, BRG1, Section 16 of the Canadian Charter of Rights and Freedoms, Bone marrow, Ciliary body, AACR, Research, American Association, Chromatin, Cancer, 2021 Essex County Council election, MDS, Association, ATPase, American Association for Cancer Research, Foghorn, Iris, Nasdaq, GLOBE, BAF, BRM, Blood, Protein, Acute leukemia, Adult, Pharmaceutical industry, Communications satellite, Vaccine, Dietary supplement

Presentations include preclinical data supporting the clinical development of the novel BAF inhibitor FHD-286 for the treatment of acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) and metastatic uveal melanoma (UM).

Key Points: 
  • Presentations include preclinical data supporting the clinical development of the novel BAF inhibitor FHD-286 for the treatment of acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) and metastatic uveal melanoma (UM).
  • Session: DDT003; New Drugs on the Horizon: Part 3
    Session: LBPO.ET02 - Late-Breaking Research: Experimental and Molecular Therapeutics 2, Section 16
    Late-breaking abstracts are under embargo until April 8, 2022, at 1:00 p.m.
  • In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.
  • Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.